From Adam to Ecstasy to Prescription MDMA Over Four Decades

Rick Doblin provides a historical overview of the development and medicinal regulation of MDMA, spanning over 40 years from its early research to ongoing Phase 3 clinical trials. The presentation highlights the transition of psychedelic research from marginalized settings to rigorous clinical frameworks, emphasizing the importance of non-profit models in advancing these substances through the FDA approval process. Practical examples illustrate how MDMA assists in processing trauma, particularly for veterans suffering from PTSD, by facilitating therapeutic breakthroughs and reducing avoidance behaviors. Finally, the talk discusses future directions in psychedelic-assisted therapy, noting the integration of clinical site networks and the ongoing pursuit of standardizing ethical guidelines to ensure long-term patient safety.